Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 66, 11571-11575, December 15, 2006. doi: 10.1158/0008-5472.CAN-06-2914
© 2006 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Horvath, A.
Right arrow Articles by Stratakis, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Horvath, A.
Right arrow Articles by Stratakis, C. A.

Priority Reports

Adrenal Hyperplasia and Adenomas Are Associated with Inhibition of Phosphodiesterase 11A in Carriers of PDE11A Sequence Variants That Are Frequent in the Population

Anelia Horvath1, Christoforos Giatzakis1, Audrey Robinson-White1, Sosipatros Boikos1, Elizabeth Levine1, Kurt Griffin1, Erica Stein1, Virginia Kamvissi1, Payal Soni1, Ioannis Bossis1, Wouter de Herder3, J. Aidan Carney4, Jérôme Bertherat5, Peter K. Gregersen6, Elaine F. Remmers2 and Constantine A. Stratakis1

1 Section on Endocrinology and Genetics, Developmental Endocrinology Branch, National Institute of Child Health and Human Resources, NIH; 2 Genetics and Genomics Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland; 3 Department of Internal Medicine, Endocrinology, Erasmus MC, Rotterdam, the Netherlands; 4 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 5 Institut National de la Sante et de la Recherche Medicale U567, Departement Endocrinologie, Metabolisme and Cancer, Institut Cochin, and Centre National de la Recherche Scientifique UMR 8104, and Centre de Reference des Maladies Rares de la Surrenale, Service d'Endocrinologie, Hôpital Cochin, Universite Paris 5, Paris, France and; 6 Feinstein Institute for Medical Research, North Shore LIJ Health System, Manhasset, New York

Requests for reprints: Constantine A. Stratakis, Section on Endocrinology and Genetics, Pediatric Endocrinology Training Program, DEB, National Institute of Child Health and Human Resources, NIH, Building 10, CRC, Room 1-3330, 10 Center Drive, MSC1103, Bethesda, MD 20892. Phone: 301-496-4686/496-6683; Fax: 301-402-0574/480-0378; E-mail: stratakc{at}mail.nih.gov.

Several types of adrenocortical tumors that lead to Cushing syndrome may be caused by aberrant cyclic AMP (cAMP) signaling. We recently identified patients with micronodular adrenocortical hyperplasia who were carriers of inactivating mutations in the 2q-located phosphodiesterase 11A (PDE11A) gene. We now studied the frequency of two missense substitutions, R804H and R867G, in conserved regions of the enzyme in several sets of normal controls, including 745 individuals enrolled in a longitudinal cohort study, the New York Cancer Project. In the latter, we also screened for the presence of the previously identified PDE11A nonsense mutations. R804H and R867G were frequent among patients with adrenocortical tumors; although statistical significance was not reached, these variants affected significantly enzymatic function in vitro with variable increases in cAMP and/or cyclic guanosine 3',5'-monophosphate levels in HeLa and HEK293 cells. Adrenocortical tissues carrying the R804H mutation showed 2q allelic losses and higher cyclic nucleotide levels and cAMP-responsive element binding protein phosphorylation. We conclude that missense mutations of the PDE11A gene that affect enzymatic activity in vitro are present in the general population; protein-truncating PDE11A mutations may also contribute to a predisposition to other tumors, in addition to their association with adrenocortical hyperplasia. We speculate that PDE11A genetic defects may be associated with adrenal pathology in a wider than previously suspected clinical spectrum that includes asymptomatic individuals. (Cancer Res 2006; 66(24): 11571-5)




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
R. Libe, A. Fratticci, J. Coste, F. Tissier, A. Horvath, B. Ragazzon, F. Rene-Corail, L. Groussin, X. Bertagna, M. L. Raffin-Sanson, et al.
Phosphodiesterase 11A (PDE11A) and Genetic Predisposition to Adrenocortical Tumors
Clin. Cancer Res., June 15, 2008; 14(12): 4016 - 4024.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
A. Horvath, V. Mericq, and C. A. Stratakis
Chest-tube insertion.
N. Engl. J. Med., February 14, 2008; 358(7): 750 - 750.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Nesterova, I. Bossis, F. Wen, A. Horvath, L. Matyakhina, and C. A. Stratakis
An Immortalized Human Cell Line Bearing a PRKAR1A-Inactivating Mutation: Effects of Overexpression of the Wild-Type Allele and Other Protein Kinase A Subunits
J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 565 - 571.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.